HomeAI · summaries
Storia in 4 fonti
India warns of misuse of low-cost weight-loss drugs as Ozempic generics enter market
NEW DELHI: India’s Health Ministry warned on Tuesday of the unregulated use of weight-loss drugs, as cheap generic versions of blockbuster diabetes medications such as Ozempic entered the market following patent expiry. The patent on semaglutide, the active ingredient in weight-loss drugs such as Ozempic and Wegovy, expired on March 20 in India, allowing local pharmaceutical companies to produce their own versions and sell them at a fraction of the original price.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
India is launching cheap, weight-loss drugs and Novo Nordisk is betting on its brands to stay on top
Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.
- ·
arabnews.com
India warns of misuse risk from cheap weight-loss jabs
India’s health ministry warned Tuesday of the risks of unregulated use of weight-loss drugs, as low-cost generic versions hit the market, stepping up inspections and enforcement…
- ·
thehindu.com
Centre intensifies regulatory surveillance over weight loss drugs
India intensifies regulatory measures on weight loss drugs to prevent unauthorized sales and ensure safe medical use.
- ·
India warns of misuse of low-cost weight-loss drugs as Ozempic generics enter market
NEW DELHI: India’s Health Ministry warned on Tuesday of the unregulated use of weight-loss drugs, as cheap generic versions of blockbuster diabetes medications such as Ozempic…
- ·
forbes.com
Indian Pharma Billionaires Pile Into Generic Weight-Loss Drugs, Sparking Regulatory Scrutiny
Last week’s expiry of the patent for semaglutide—the active ingredient in Novo Nordisk’s blockbuster drugs Wegovy and Ozmepic that are used to treat both diabetes and…